jimmy667 - Spot on! NWBO officially cornered the DC based immunotherapy space, when it announced the in-licensing deal with Roswell on June 24th 2024. Any serious long should read pgsd's AI generated post, which provides a breathtaking overview of Roswell's patent portfolio. The patents represent the culmination of 24 years of research. The desperate housewives bantering of management failures to deliver much earlier falls short. The long thesis is supported by the belief in the strength of the science, but that's where it hits a wall. Setting aside the bear's incapacity to argue against the science, hence why actual science contributors have been sanctioned here, it became clear on June 24th, that NWBO was not in a position to fetch the kind of valuation, as was assumed before that date. In fact, Roswell submitted its most recent family of patents in 2023. Additionally, we have seen a string of Flaskworks patents rolling in through 2024, and as recently as this year. So in an environment where manipulation has proven to be the norm, and continues to be, management has never missed a beat in its progressive devouring of the DC space, and finishing touch, with its ongoing refinement of its revolutionary Flaskworks unit, which promises to deliver scale, and deep cost reduction. To be clear, as hard, and as frustrating the MHRA approval is taking, NWBO is continuously adding incremental value. Now that's something that can't be manipulated. This understanding, imo, falls in line with what LP meant, when at the June 29th ASM, she proclaimed, "We will be a much different company in 18 months!"
Market Data 
Markets 
AI
